Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines.
作者： Maria Petrecz , Camilo J. Acosta , Stephanie O. Klopfer , Barbara J. Kuter , Michelle G. Goveia
DOI: 10.1080/21645515.2018.1530934
关键词:
摘要: Safety and immunogenicity data from 5 clinical trials conducted in the US children 12-to-23 months old where HAVi was administered alone or concomitantly with other pediatric vaccines (M-M-R®II,...
sci-hub.se 参考文章(31)
STAN L. BLOCK, JAMES A. HEDRICK, RONALD D. TYLER, R. ALAN SMITH, GARY CALANDRA, CAROLYN PATTERSON, JOHN LEWIS, ROBERT SITRIN, WILLIAM MILLER, SKAI SCHWARTZ, BRIAN WIENS, DAVID NALIN, Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children. Pediatric Infectious Disease Journal. ,vol. 12, pp. 976- 980 ,(1993) , 10.1097/00006454-199312000-00002
Paul Coplan, Steven Black, Henry Shinefield, John Hansen, Edwin Lewis, Ling Su, A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine. ,vol. 22, pp. 766- 772 ,(2004) , 10.1016/J.VACCINE.2003.08.034
Yaffa Ashur, Ruth Adler, Mina Rowe, Daniel Shouval, Comparison of immunogenicity of two hepatitis A vaccines — VAQTA® and HAVRIX® — in young adults Vaccine. ,vol. 17, pp. 2290- 2296 ,(1999) , 10.1016/S0264-410X(98)00480-0
Thomas Linglöf, Jan van Hattum, Karen M Kaplan, Jennifer Corrigan, Isabelle Duval, Erin Jensen, Barbara Kuter, An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. Vaccine. ,vol. 19, pp. 3968- 3971 ,(2001) , 10.1016/S0264-410X(01)00134-7
Brian L. Wiens, Norman R. Bohidar, Joseph G. Pigeon, James Egan, William Hurni, Leora Brown, Barbara J. Kuter, David R. Nalin, Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. Journal of Medical Virology. ,vol. 49, pp. 235- 241 ,(1996) , 10.1002/(SICI)1096-9071(199607)49:3<235::AID-JMV13>3.0.CO;2-B
Nadav Orr, Eyal Klement, David Gillis, Tamar Sela, Raid Kayouf, Estela Derazne, Itamar Grotto, Ran Balicer, Michael Huerta, Lisa Aviram, Ruhama Ambar, Yoram Epstein, Yuval Heled, Dani Cohen, Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines Vaccine. ,vol. 24, pp. 4328- 4332 ,(2006) , 10.1016/J.VACCINE.2006.03.010
Fernando A. Guerra, Jacqueline Gress, Alan Werzberger, Keith Reisinger, Emmanuel Walter, Hassan Lakkis, Anthony D. Grosso, Carolee Welebob, Barbara J. Kuter, Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatric Infectious Disease Journal. ,vol. 25, pp. 912- 919 ,(2006) , 10.1097/01.INF.0000238135.01287.B9
WENDY NEWCOMER, BETH RIVIN, RAYMOND REID, LAWRENCE H. MOULTON, MARK WOLFF, JANNE CROLL, CAROL JOHNSON, LEORA BROWN, DAVID NALIN, MATHURAM SANTOSHAM, Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children. Pediatric Infectious Disease Journal. ,vol. 13, pp. 640- 642 ,(1994) , 10.1097/00006454-199407000-00011
Richard Hornick, Richard Tucker, Karen M. Kaplan, Karen A. Eves, Dalfoni Banerjee, Erin Jensen, Barbara Kuter, A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity. Vaccine. ,vol. 19, pp. 4727- 4731 ,(2001) , 10.1016/S0264-410X(01)00224-9
Jean Henrik Braconier, Solveig Wennerholm, S.Ragnar Norrby, Comparative immunogenicity and tolerance of Vaqta™ and Havrix™ Vaccine. ,vol. 17, pp. 2181- 2184 ,(1999) , 10.1016/S0264-410X(98)00352-1